Corbus Pharmaceuticals Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Corbus Pharmaceuticals Holdings, Inc. on April 16, 2015. The report details a significant corporate event regarding the company's stock listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance and listing event rather than financial performance.
Material Changes
- Nasdaq Uplisting: On April 16, 2015, the Company commenced trading on the Nasdaq Capital Market under the symbol "CRBP".
- Abandonment of Reverse Stock Split: As a direct result of the successful uplisting to the Nasdaq Capital Market, the Board of Directors abandoned its prior authorization for a reverse stock split.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document is limited to the notification of the trading commencement and the cancellation of the reverse stock split.
Key Facts for Investor Verification
- Verify the new trading symbol "CRBP" on the Nasdaq Capital Market.
- Confirm that the previously authorized reverse stock split is no longer in effect.
- Review the Company's most recent 10-Q or 10-K for financial data, as this 8-K does not contain financial statements.